ALDX Aldeyra Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1341235 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY55.7%
TTM EPS YoY57.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.3%
ROA-31.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets18.8%
Debt / equity0.00x
Current ratio5.45x
Interest coverage-21.39x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $25.66M | $48.22M | $29.46M | $47.31M | $44.94M |
| SG&A expense | $9.60M | $11.89M | $13.34M | $15.37M | $11.28M |
| Operating income | -$35.27M | -$60.12M | -$42.79M | -$62.68M | -$56.22M |
| Interest expense | $1.91M | $1.93M | $2.07M | $1.69M | $1.74M |
| Pretax income | $33.85M | $55.85M | — | — | -$57.78M |
| Income tax | $0 | $1,000 | $0 | $0 | $0 |
| Net income | -$33.85M | -$55.85M | -$37.54M | -$62.02M | -$57.78M |
| EBITDA | -$35.01M | -$59.87M | -$42.53M | -$62.42M | -$55.96M |
| EPS (basic) | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 |
| EPS (diluted) | -0.56 | -0.94 | -0.64 | -1.06 | -1.07 |
| Weighted avg. shares (diluted) | 60.06M | 59.48M | 58.94M | 58.41M | 54.04M |
| Balance sheet | |||||
| Cash & equivalents | $70.04M | $54.53M | $142.82M | $144.42M | $229.79M |
| Short-term investments | $0 | $46.62M | $0 | $29.88M | $0 |
| Current assets | $71.78M | $104.07M | $147.81M | $181.02M | $232.75M |
| PP&E, net | $0 | $0 | $5,764 | $19,279 | $32,487 |
| Total assets | $72.06M | $104.61M | $148.33M | $181.29M | $233.14M |
| Current liabilities | $27.81M | $18.60M | $22.26M | $15.36M | $11.77M |
| Short-term debt | $15.25M | $31,372 | $15.15M | $911,763 | — |
| Long-term debt | $0 | $15.00M | $0 | $14.92M | $15.50M |
| Total debt | $15.25M | $15.03M | $15.15M | $15.83M | $15.50M |
| Total liabilities | $27.81M | $33.60M | $28.53M | $30.28M | $27.40M |
| Shareholders' equity | $44.25M | $71.00M | $119.80M | $151.01M | $205.74M |
| Net debt | -$54.79M | -$39.50M | -$127.68M | -$128.58M | -$214.29M |
| Shares outstanding | 60.16M | 59.65M | 59.20M | 58.56M | 58.08M |
| Cash flow statement | |||||
| Operating cash flow | -$33.35M | -$43.21M | -$30.33M | -$56.64M | -$42.56M |
| Capital expenditure | — | — | $0 | $16,317 | $7,806 |
| Free cash flow | — | — | -$30.33M | -$56.65M | -$42.56M |
| Investing cash flow | $47.74M | -$44.92M | $30.00M | -$29.95M | -$7,806 |
| Financing cash flow | $1.12M | -$171,422 | -$1.27M | $1.22M | $194.50M |
| Depreciation & amortization | $251,993 | $249,623 | $262,780 | $258,707 | $264,180 |
| Stock-based compensation | $6.09M | $7.97M | $5.75M | $8.29M | $7.11M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.